Third-party testing verification adds credibility
In the CY 2024 PFS final rule (88 FR 79057), we stated that we do not consider the following to be unique circumstances warranting an increased applicable percentage at this time: weight-based doses, BSA-based doses, varying surface area of a wound, loading doses, escalation or titration doses, tapering doses, and dose adjustments for toxicity because we believe manufacturers can optimize the availability of products for these circumstances to limit the percentage of discarded units for a drug, unlike the circumstances of manufacturers of drugs that require filtration during the preparation process, as described in section 1847A(h)(8)(B)(ii) of the Act
Steven Top Reviewer 7 ratings|6 reviews Excellent customer care and really good price for product
These rules help healthcare professionals give safe and effective treatment
A tuftsin analog with the same Pro-Gly-Pro stabilizing motif, developed by the same institute, studied mainly as an anxiolytic acting through GABAergic and related pathways